BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study

  March 31, 2025

   · 

  8 min read
• Press Releases

  AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

  March 31, 2025

   · 

  7 min read
• Press Releases

  UZLeuven and VIB-KU Leuven Announce First Patient Treated in Ground-Breaking Malignant Melanoma Study

  March 31, 2025

   · 

  4 min read
• Press Releases

  New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

  March 31, 2025

   · 

  20 min read
• Press Releases

  Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

  Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3rd Cohort now fully enrolled in on-going clinical study

  March 31, 2025

   · 

  11 min read
• Press Releases

  ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

  March 31, 2025

   · 

  7 min read
• Press Releases

  Adagio Medical Reports Fourth Quarter and Full Year 2024 Results

  March 31, 2025

   · 

  6 min read
• Press Releases

  Late-Breaking Clinical Trial Presented at the American College of Cardiology Supports Low-Dose Colchicine, 0.5 mg to Treat Cardiovascular Disease by Reducing Progression of Coronary Plaque

  March 31, 2025

   · 

  6 min read
• Press Releases

  WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

  March 31, 2025

   · 

  12 min read
• Press Releases

  Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

  March 31, 2025

   · 

  1 min read